📊 APRE Key Takeaways
Is Aprea Therapeutics, Inc. (APRE) a Good Investment?
Aprea Therapeutics is a pre-revenue pharmaceutical company with severe cash burn and no near-term revenue generation, having consumed $12.9M in operating cash flow with only $14.6M in cash remaining. The company faces an acute liquidity crisis as current cash reserves provide less than 14 months of runway at current burn rates, with no clear path to profitability or revenue generation visible in the financial statements.
Aprea Therapeutics shows weak fundamentals as a pre-revenue business with persistent operating and net losses, deeply negative returns on equity and assets, and negative free cash flow. While the balance sheet is currently clean with high cash relative to liabilities and no long-term debt, the annual cash burn is close to the current cash balance, which raises material funding and dilution risk if operating performance does not improve.
Why Buy Aprea Therapeutics, Inc. Stock? APRE Key Strengths
- Strong immediate liquidity position with $14.6M cash and 5.63x current ratio
- Minimal debt burden with zero long-term debt and 0.0x debt/equity ratio
- Recent insider activity with 4 Form 4 filings in last 90 days indicating some management engagement
- Strong liquidity with a 5.63x current and quick ratio
- Low financial leverage with no long-term debt and 0.00x debt-to-equity
- Cash of $14.60M materially exceeds total liabilities of $3.95M
APRE Stock Risks: Aprea Therapeutics, Inc. Investment Risks
- No revenue generation with operating losses of -$13.2M and negative operating margin indicating early-stage pre-commercial status
- Severe cash burn rate of -$12.9M in operating cash flow with less than 14 months of cash runway at current rates
- Negative returns on equity (-101.3%) and assets (-79.1%) demonstrate value destruction with no visible path to profitability
- Pre-revenue pharmaceutical company faces extremely high clinical development and regulatory approval risk with unclear pipeline maturity
- No reported revenue, limiting visibility into commercial traction and growth quality
- Sustained losses with operating income of -$13.23M and free cash flow of -$12.91M
- High cash burn relative to cash on hand suggests a limited runway and likely need for external financing
Key Metrics to Watch
- Quarterly operating cash burn rate and remaining cash runway
- Clinical trial progress and regulatory milestone announcements
- Capital raising activities and dilution impact on existing shareholders
- Quarterly operating cash burn versus cash balance
- Any emergence of recurring revenue or meaningful reduction in net loss
Aprea Therapeutics, Inc. (APRE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.63x current ratio provides a solid financial cushion.
APRE Profit Margin, ROE & Profitability Analysis
APRE vs Healthcare Sector: How Aprea Therapeutics, Inc. Compares
How Aprea Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aprea Therapeutics, Inc. Stock Overvalued? APRE Valuation Analysis 2026
Based on fundamental analysis, Aprea Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aprea Therapeutics, Inc. Balance Sheet: APRE Debt, Cash & Liquidity
APRE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aprea Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.35 indicates the company is currently unprofitable.
APRE Revenue Growth, EPS Growth & YoY Performance
Aprea Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
APRE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aprea Therapeutics, Inc. (CIK: 0001781983)
📋 Recent SEC Filings
❓ Frequently Asked Questions about APRE
What is the AI rating for APRE?
Aprea Therapeutics, Inc. (APRE) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are APRE's key strengths?
Claude: Strong immediate liquidity position with $14.6M cash and 5.63x current ratio. Minimal debt burden with zero long-term debt and 0.0x debt/equity ratio. ChatGPT: Strong liquidity with a 5.63x current and quick ratio. Low financial leverage with no long-term debt and 0.00x debt-to-equity.
What are the risks of investing in APRE?
Claude: No revenue generation with operating losses of -$13.2M and negative operating margin indicating early-stage pre-commercial status. Severe cash burn rate of -$12.9M in operating cash flow with less than 14 months of cash runway at current rates. ChatGPT: No reported revenue, limiting visibility into commercial traction and growth quality. Sustained losses with operating income of -$13.23M and free cash flow of -$12.91M.
What is APRE's revenue and growth?
Aprea Therapeutics, Inc. reported revenue of N/A.
Does APRE pay dividends?
Aprea Therapeutics, Inc. does not currently pay dividends.
Where can I find APRE SEC filings?
Official SEC filings for Aprea Therapeutics, Inc. (CIK: 0001781983) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is APRE's EPS?
Aprea Therapeutics, Inc. has a diluted EPS of $-1.93.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is APRE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Aprea Therapeutics, Inc. has a STRONG SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is APRE stock overvalued or undervalued?
Valuation metrics for APRE: ROE of -101.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy APRE stock in 2026?
Our dual AI analysis gives Aprea Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is APRE's free cash flow?
Aprea Therapeutics, Inc.'s operating cash flow is $-12.9M, with capital expenditures of $15.5K.
How does APRE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -101.3% (avg: 15%), current ratio 5.63 (avg: 2).